This is an observational, prospective, non-interventional and multi-centre study, to assess the impact of androgen ablation therapy in blood triglycerides, cholesterol and glucose, body fat distribution and fracture risk to ten years using FRAX model in patients with prostate cancer. The patients will be following for 12 months

Inclusion Criteria:

• Prostate cancer patient requiring androgen-ablation treatment: LHRH analogs, surgical castration, antiandrogen treatment
• Provision of informed consent prior to conducting any study-related procedure

Exclusion Criteria:

• Patient involved in a Clinical Trial

Prostate cancer patients in androgen-ablaction treatment in urological departments